Targeted therapy for neuroendocrine tumors

Feb. 16, 2023—Cancer therapies that target VEGF receptor appear safe and effective for patients with pancreatic and non-pancreatic neuroendocrine tumors, meta-analysis of phase 2/3 clinical trials demonstrates.

Read more